Cointime update: Novo Nordisk said China’s National Medical Products Administration has accepted its marketing application for CagriSema (cagrilintide and semaglutide injection) for long-term weight management. The fixed-dose combination pairs a long-acting amylin receptor agonist with the GLP-1 receptor agonist semaglutide and is given as a once-weekly subcutaneous injection. The two components act through distinct, complementary mechanisms on appetite and body-weight regulation pathways.
China NMPA Accepts Novo Nordisk’s CagriSema Weight-Loss Drug Application
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
3h ago
House Democrats Target Trump Inner Circle in First Oversight Requests
3h ago
US Democrats Plan Data Center Power Reform, Operators May Pay $35B More Over 10 Years
3h ago
Democrats to Probe Trump’s $100B Venezuela Oil Deal
5h ago
UBS Global Wealth Management Forecasts S&P 500 at 8,200 by End-2027
5h ago
Tencent Q3 2026 Revenue Rises 8% to RMB 207.3 Billion
5h ago
Onshore yuan closes at 6.6653 per dollar, up 2 pips